Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1994-09-22
1997-09-30
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4242311, 435 691, 4351723, 435 693, 514 12, A61K 39245, C12N 1538, C12P 2102
Patent
active
056723490
ABSTRACT:
A process for obtaining Herpes Simplex virus type 1 (HSV-1) glycoprotein I (gI) from cells which have been infected or transformed with a recombinant Baculovirus is disclosed. The gI produced is then isolated and purified for use in immunotherapy against HSV infections.
REFERENCES:
patent: 4859587 (1989-08-01), Roizman
patent: 4891315 (1990-01-01), Watson et al.
Atherton, "Protection from retinal necrosis by passive transfer of monoclonal antibody specific for herpes simplex virus glycoprotein D," Current Eye Research 11(1):45-52 (1992).
Foster et al., "lmmunomodulation of experimental murine herpes simplex keratitis: H. Glycoprotein D protection," Current Eye Research 2(11):1051-1061 (1988).
Ghiasi et al., "Expression of herpes simplex virus type 1 glycoprotein B in insect cells," Virus Research 22(1):35-39 (1991).
Ghiasi et al., "High Level Expression of Each of the Seven Herpes Simplex Virus Glycoproteins in Insect Cells Using Baculovirus Expression Vectors: Subsequent Use as Vaccines," Invest. Ophthalmol. Visual Sci., 32(4):806 (1991).
Ghiasi et al., "Immunoselection of recombinant baculoviruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D," Arch. Virol. 121:163-178 (1991).
Kino et al., "Immunogenicity of herpes simplex virus glycoprotein gB-1-related protein produced in yeast," Vaccine 2(2): 155-160 (1989).
Lausch et al., "Prevention of Herpes Keratitis by Monoclonal Antibodies Specific for Discontinuous and Continuous Epitopes on Glycoprotein D," Invest. Ophthal. Visual Sci. 32(10):2735-2740 (1991).
Nesburn et al., "Efficacy and Safety of `Therapeutic` Systemic HSV Vaccines in the Rabbit Ocular Recurrence Model," Invest. Ophthalmol. Visual Sci. 32(4):854 (1991).
Krishna et al. (1989) J. gen. Virol. 70: 1805-1814.
Ghiasi et al. (1992) Baculovirus-expressed glycoprotein H of herpes simplex virus type 1 (HSV-1) induces neutralizing antibody and delayed type hypersensitivityresponses, but does not protect immunized mice against lethal HSV-1 challenge. Journal of Ge.
Krishna et al (1989) J. gen Virol. 70 1805-1814.
Klein, R.J., Reinfections and site-specific immunity in herpes simplex virus infections. Vaccine, 7:380-381 (1989).
Stanberry, L.R. et al., Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J. Infec. Dis., 157:156-63 (1988).
Kern, A.B. et al., Vaccine Therapy in Recurrent Herpes Simplex. Arch. Derm., 89:844-845 (1964).
Frenkel, L. et al., A randomized double blind, placebo-controlled phase 1 trial of a herpes simplex virus purified glycoprotein (gD1) vaccine. Interscience Conf. on Antimicrobial Agents & Chemo., 206 (1990).
Berman, P.W. et al., Efficacy of Recombinant Glycoprotein D Subunit Vaccines on the Development of Primary, Recurrent, and Latent Genital Infections With Herpes Simplex Virus Type 2 in Guinea Pigs. J. Infec. Dis., 157(5):897-902 (May 1988).
Blacklaws, B. et al., Immunogenicity of herpes simplex type 1 glyco-proteins expressed in vaccinia virus recombinants. Virology, 177:727-736 (1990).
Stanberry, L.R. et al., Heterologous Versus Homologous Herpes Simplex Virus Glycoprotein Immunotherapy of Recurrent Genital Herpes. Pediatr. Res., 25:191A, Part 2 (1989).
Rock, D.L., Nesburn, A.B. et al., Detection of latency related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J. Virol., 61:3820-26 (1987)..
Matsuura, Y. et al., Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins. J. Gen. Virol., 68:1233-50 (1987).
Lee, G.T. et al., Location of the structural genes for glycoproteins gD and gE and for other polypeptides in the S component of herpes simplex virus type 1 DNA. J. Virol., 43:41-49 (1982).
Mathews, J.T. et al., Synthesis and processing glycoprotein D of herpes simplex virus types 1 and 2 in an in vitro system. J. Virol., 48:521-53 (1983).
Ghiasi, H., et al., Call surface expression of herpes simplex virus type 1 glycoprotein H in recombinant baculovirus infected cells. Virology, 185:187-194 (1991).
Morein, B. et al., Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature, 308:457-60 (1984)..
Shimormura, Y. et al., Shedding by iontophoresis of 6-hydroxdopamine followed by topical epinephrine. Invest. Ophthalmol., 24:1588-90 (1983).
Nesburn, A.B. et al., Isolation of herpes simplex virus: Isolation free rabbit trigeninal ganglia between episodes of recurrent ocular infection. Arch. Ophthalmol., 88:412-17 (1972).
Nesburn, A.B. et al., Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection. Invest. Ophthalmol. Vis. Sci., 31:77-82 (1990).
Sullivan, V. and Smith, G.L. The Herpes Simplex Virus Type 1 US7 Product is a 66K Glycoprotein and Is A Target for Complement-dependent Virus Neutralization. J. Gen. Virol., 69:859-867 (1988).
Johnson, D.C. and Feenstra, V. Identification of a Novel Herpes Simplex Virus Type 1 induced glycoprotein which complexes with gE and binds immunoglobulin. J. Virol., 61:2208-2216 (1987).
Ghiasi Homayon
Nesburn Anthony Bart
Wechsler Steven Lewis
Bugaisky G. E.
Cedars Sinai Medical Center
Wax Robert A.
LandOfFree
Process for the expression of herpes simplex virus type 1 glycop does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the expression of herpes simplex virus type 1 glycop, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the expression of herpes simplex virus type 1 glycop will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2255031